Intas Pharmaceuticals’ new warning letter from the U.S. FDA reads like a checklist of what not to do when the regulator pays a visit to your manufacturing facility. The FDA handed Intas a five ...

Last November, an employee at Intas Pharmaceuticals, which makes several widely used chemotherapies that are in short supply, was seen pouring acetic acid in a trash bin containing documents at a ...

Coherus has agreed to sell its biosimilar Udenyca—which references Amgen’s febrile neutropenia drug Neulasta—to Intas Pharmaceuticals for up to $558.4 million. The deal, which is expected to ...

Gujarat-based drugmaker Intas Pharmaceuticals Ltd., which counts private equity firm ChrysCapital, Singapore state investment firm Temasek and Abu Dhabi Investment Authority (ADIA) as its investors, ...

to Intas Pharmaceuticals Ltd. (Intas) pursuant to the asset purchase agreement (the Agreement) dated December 2, 2024 between Coherus and Intas in a deal valued at up to $558.4 million.

A Triangle pharmaceutical firm is expanding its portfolio as its parent company completes a $500 million deal. © 2025 American City Business Journals. All rights ...

Intas Pharmaceuticals Limited has informed that its manufacturing facility SEZ (Pharmez) near Ahmedabad has been listed under ‘Import Alert’ by the US Food and Drug Administration (USFDA).